ArticleToxins2023
Production of AFB1 High-Specificity Monoclonal Antibody by Three-Stage Screening Combined with the De-Homologation of Antibodies and the Development of High-Throughput icELISA.
Article in Toxins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To achieve accurate detection of AFB1 toxin content in agricultural products and avoid false-positive rates in the assays, the specificity of mAbs is critical. We improved the specificity of the prepared monoclonal antibodies by modifying the traditional limiting dilution subcloning method. The traditional finite dilution method was modified with three-stage screening (the trending concentration of standards used in the screening is low-high-low) to achieve high specificity in pre-cell screening and increased the number of subclones to 10 to achieve the de-homologation of antibodies. A modified limiting dilution obtained a highly specific AFB1 monoclonal cell line, ZFG8, with a 50% inhibition concentration (IC50) of 0.3162 ng/mL. Notably, it exhibited the highest specificity compared to anti-AFB1 monoclonal antibodies prepared by other investigators. The maximum cross-reactivity of the mAb with structural analogues for AFB2, AFG1, AFG2, and AFM1 was 0.34%. The results showed that this type of screening improves the monoclonal antibodies' specificity. Based on this ZFG8 monoclonal antibody, an icELISA assay was established with an IC50 of 0.2135 ng/mL for AFB1. The limit of the linear detection range of icELISA is 0.0422-1.29267 ng/mL with reasonable specificity and precision. The recoveries of AFB1 in samples of corn flour and wheat meal ranged from 84 to 107%, with CVs below 9.3%. The recoveries of structural analogues (AFB2, AFM1, AFG1, and AFG2) were less than 10% in both corn flour and wheat meal. The results showed that the prepared AFB1 monoclonal antibody could accurately and specifically recognize AFB1 residues in agricultural products while ignoring the effects of other structural analogues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.